

Tumour-associated trypsin inhibitor, carcinoembryonic proteins CRP and $\hat{I}\pm 1$ -antitrypsin in patients with gastr

Clinical Biochemistry

37, 56-60

DOI: 10.1016/j.clinbiochem.2003.09.002

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cancer and Inflammation. , 2004, , .		2
2	Nanoprobe-Based Affinity Mass Spectrometry for Selected Protein Profiling in Human Plasma. Analytical Chemistry, 2005, 77, 5990-5997.	3.2	77
3	Ethylene Glycol-Protected Magnetic Nanoparticles for a Multiplexed Immunoassay in Human Plasma. Small, 2006, 2, 485-489.	5.2	140
4	Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. Journal of Pathology, 2006, 209, 147-156.	2.1	125
5	Nanomaterial Based Affinity Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry for Biomolecules and Pathogenic Bacteria. Recent Patents on Nanotechnology, 2007, 1, 99-111.	0.7	27
6	Targeted protein quantitation and profiling using PVDF affinity probe and MALDI-TOF MS. Proteomics, 2007, 7, 3038-3050.	1.3	17
7	Serological Proteomics of Gastritis: Degradation of Apolipoprotein A-I and Alpha1-Antitrypsin Is a Common Response to Inflammation Irrespective of Helicobacter pylori Infection. Digestive Diseases and Sciences, 2008, 53, 3112-3118.	1.1	8
8	Multiplexed Immunoassay: Quantitation and Profiling of Serum Biomarkers Using Magnetic Nanoprobos and MALDI-TOF MS. Analytical Chemistry, 2008, 80, 6159-6167.	3.2	77
9	Identification of trypsinâ€™inhibitory site and structure determination of human SPINK2 serine proteinase inhibitor. Proteins: Structure, Function and Bioinformatics, 2009, 77, 209-219.	1.5	19
10	Peptidomimeticâ€™functionalized carbon nanotubes with antitrypsin activity. Carbon, 2009, 47, 3550-3558.	5.4	15
11	Can the Acute-Phase Reactant Proteins be Used as Cancer Biomarkers?. International Journal of Biological Markers, 2010, 25, 1-11.	0.7	47
12	Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. BMC Cancer, 2010, 10, 498.	1.1	26
13	Alpha-1 Antitrypsin Deficient Squamous Cell Carcinoma of Esophagus in the Azeri Population of Iran. Laboratory Medicine, 2010, 41, 613-618.	0.8	3
14	Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients. Radiation Oncology, 2011, 6, 100.	1.2	5
15	Structural Features, Biological Functions of the Alpha-1 Antitrypsin and Contribution to Esophageal Cancer. , 0, , .		3
16	Global Gene Expression Profiling Reveals SPINK1 as a Potential Hepatocellular Carcinoma Marker. PLoS ONE, 2013, 8, e59459.	1.1	67
17	TATI as a biomarker. Clinica Chimica Acta, 2014, 431, 260-269.	0.5	33
18	A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia. Biomarker Research, 2016, 4, 1.	2.8	42

#	ARTICLE	IF	CITATIONS
19	Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI. <i>Tumor Biology</i> , 2016, 37, 9367-9374.	0.8	8
20	Proteome analysis of sheep B lymphocytes in the course of bovine leukemia virus-induced leukemia. <i>Experimental Biology and Medicine</i> , 2017, 242, 1363-1375.	1.1	4
21	Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer. <i>Acta Oncol</i> , 2020, 59, 681-688.	0.8	6
22	Cancer as a chronic inflammatory disease: role of immunotherapy. , 2004, , 21-51.		3
23	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. <i>PLoS ONE</i> , 2016, 11, e0165615.	1.1	31
24	Alpha-1 Antitrypsin Blood Levels as Indicator for the Efficacy of Cancer Treatment. <i>World Journal of Oncology</i> , 2013, 4, 83-86.	0.6	9
25	Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins. <i>PeerJ</i> , 2016, 4, e2450.	0.9	17
26	Inflammation, necrosis, and cancer. , 2004, , 189-196.		2
28	Evaluation of TATI marker assays – the pancreatic trypsin inhibitor – in patients with endometrial cancer with unfavorable predictors. <i>Current Gynecologic Oncology</i> , 2013, 11, 103-114.	0.1	0
29	New intracellular and molecular aspects in pathophysiology of colorectal cancer. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2011, 4, 43-52.	0.6	2
30	TATI, TAT-2, and CRP as Prognostic Factors in Colorectal Cancer. <i>Oncology</i> , 2022, 100, 22-30.	0.9	3